Due to the site upgrade, your MY ACCOUNT logins will need to be updated. Please access Forgot Your Password to make this change. If you do not have an account, click here.

Strong evidence that Glucosamine with Chondroitin Protect Adults from Colon and Rectal Cancers

Aug 01, 2016

Strong evidence that Glucosamine with Chondroitin Protect Adults from Colon and Rectal Cancers 

The supplements Glucosamine and Chondroitin have strong evidence that they reduce joint pain and stiffness, and improve joint function as well as the prescription drug celecoxib (generic Celebrex), that they are much safer, and have the additional benefit of slowing down the degradation of joint cartilage; something the drugs have no ability to do.

However, studies from high quality academic institutions also show that Glucosamine with Chondroitin have other benefits. A study in 2015 shows the supplements decrease generalized inflammation as measured by the metric CRP; Harvard School of Public Health, Vanderbilt University, and the Fred Hutchinson Cancer Research Center published this research in the journal PloS One. Researchers at the University of North Carolina at Chapel Hill after reviewing data from the Vital Study report that use of either supplement may reduce the risks of lung cancer, colon cancer, and rectal cancer. Their report was published in the journal Cancer Epidemiology, Biomarkers, and Prevention as far back as 2009. In 2011 tht eFred Hutchinson Cancer Research Center reported that using Glucosamine over a 10-year period reduced the risk of lung cancer even in smokers by 33%, and this was not influenced by subsequent use of NSAIDs which are thought to have anticancer effects. If the research, which included data on 77,000 adults, was restricted to adenocarcinoma of the lung Glucosamine lowered the risk by 51%.

Reporting their findings in the June 30th, 2016 issue of the International Journal of Cancer researchers from leading cancer research institutes give strong support for Glucosamine with Chondroitin’s cancer preventing benefit. The research shows that any use of Glucosamine in conjunction with Chondrotin lowers the risk of colon and rectal cancer by up to 25%. Using Chondroitin alone but not Glucosamine alone also lowered the risk. NSAIDs such as aspirin and ibuprofen have a known ability to lower the risk of developing colon cancer. However, even with the use of NSAIDs, Glucosamine with Chondroitin still offered the additional benefit against colorectal cancers. Weight and the level of body fat, the amount of exercise nor lack of it, nor gender interfered with the supplements protective effects and the level of protection varied little between colon and rectal cancer; the supplement protected equally well against either.

The researchers are from Memorial Sloan Kettering Cancer Center, The Harvard School of Public Health, The Department of Medical Oncology at the Dana-Farber Cancer Institute and Harvard Medical School, Massachusetts General Hospital, Brigham and Women’s Hospital, and the National Cancer Institute’s Division of Cancer Prevention.